The wt FLT3/wt CBL and mutant FLT3/wt CBL primary cells generally showed more sensitivity to the inhibitors (at 1000 nmol/L) than the mutant CBL‐expressing AML samples (Figure 2B,D). The gene discussed is CBL; the disease is acute myeloid leukemia.